Direct-acting antivirals (DAAs) have revolutionized hepatitis C virus (HCV) treatment, achieving sustained virological response (SVR) in over 97% of patients. However, managing patients post-SVR, especially those without advanced fibrosis, compensated advanced chronic liver disease (cACLD), or decompensated cirrhosis, presents new challenges. This position statement provides guidance on appropriate follow-up care, hepatocellular carcinoma (HCC) risk assessment, and managing extrahepatic manifestations, along with recommendations for monitoring at-risk patients for reinfection. The aim is to help healthcare professionals optimize post-treatment care for patients cured of HCV.

The statement also highlights the needs of specific patient groups, including those with cACLD, HCC, and extrahepatic manifestations like cryoglobulinemia. It stresses the importance of regular screening and specialized care for patients with cirrhosis, who are at high risk for complications. The role of nurse practitioners in monitoring and managing these patients is key, with an emphasis on comprehensive follow-up and interventions to prevent reinfection, particularly in high-risk populations like people who inject drugs (PWID) and men who have sex with men (MSM). In addition, the statement also outlines individualized HCC surveillance strategies post-SVR and the potential role of new risk stratification models.

Reference: Reiberger T, Lens S, Cabibbo G, et al. EASL position paper on clinical follow-up after HCV cure. J Hepatol. 2024 Aug;81(2):326-344.